Drug intelligence / Profile preview

FMC-2

Development stage: Preclinical
Lead developer: FimmCyte
Modality: Antibody-Based Therapeutics

Overview

FMC-2 is a preclinical therapeutic antibody candidate being developed by FimmCyte for the treatment of endometriosis and potentially other inflammatory gynecologic conditions.[4][6] It is part of FimmCyte’s antibody-based pipeline focused on endometriosis and inflammation, although specific target, isotype, and detailed mechanism of action have not been publicly disclosed; FMC-2 is currently described only as an antibody program in lead optimization or preclinical development.[4][6]

Targets

CD3 (T-cell surface glycoprotein CD3)FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on FMC-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FMC-2.

Explore the full profile